AptarGroup Q2 2022 Earnings Report
Key Takeaways
AptarGroup reported a positive second quarter with a 4% increase in reported sales and a 15% increase in net income. Core sales grew by 10%, and adjusted EBITDA increased by 8%. The company is focused on pricing initiatives and managing expenses to drive shareholder return.
Reported sales grew 4% and net income increased 15% to $64 million.
Core sales increased 10% and adjusted EBITDA increased 8% to $160 million.
Reported earnings per share increased 17% to $0.95 compared to $0.81 in the prior year.
Each segment achieved sales growth through improved volume as well as increased pricing, with Pharma and Beauty + Home segments reaching double-digit core sales growth.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Forward Guidance
Aptar expects earnings per share for the third quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.90 to $1.00.
Positive Outlook
- Pharma segment’s prescription drug and consumer health care markets are expected to continue strong momentum in the coming quarter.
- Well positioned to navigate a potential economic downturn due to the strength of our balance sheet
- Disciplined approach to capital management
- Broad portfolio of innovative solutions
- Serve multiple essential markets
Challenges Ahead
- Rising inflation
- Ongoing war in Ukraine
- Supply chain disruptions
- Very tight U.S. labor market
- The stronger dollar is expected to continue to have an impact on our results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income